What do estimates of working memory capacity tell us?

May 10, 2017 by in NEUROLOGY Comments Off on What do estimates of working memory capacity tell us?

Related posts: What do working memory span tasks like reading span really measure? Implications from cognitive neuropsychology for models of short-term and working memory A hierarchical biased-competition model of domain-dependent…

read more

Working memory

May 10, 2017 by in NEUROLOGY Comments Off on Working memory

1 Working memory Past, present…and future? Alan Baddeley Graham Hitch As the longest serving residents of the province of working memory, the two of us have been invited to introduce…

read more

Summary

May 10, 2017 by in NEUROLOGY Comments Off on Summary

© Springer International Publishing Switzerland 2015Raymond A. Huml (ed.)Muscular Dystrophy10.1007/978-3-319-17362-7_15 15. Summary Raymond A. Huml1   (1) Biosimilars Center of Excellence, Quintiles Inc., 4820 Emperor Boulevard, Durham, NC 27703, USA     Raymond A. Huml Email: raymond.huml@quintiles.com Muscular dystrophy (MD)…

read more

Global and National Patient Registries

May 10, 2017 by in NEUROLOGY Comments Off on Global and National Patient Registries

© Springer International Publishing Switzerland 2015Raymond A. Huml (ed.)Muscular Dystrophy10.1007/978-3-319-17362-7_14 14. Global and National Patient Registries Raymond A. Huml1   (1) Biosimilars Center of Excellence, Quintiles Inc., 4820 Emperor Boulevard, Durham, NC 27703, USA     Raymond A. Huml Email:…

read more

U.S. Patient Advocacy Groups

May 10, 2017 by in NEUROLOGY Comments Off on U.S. Patient Advocacy Groups

(1) ℅ Raymond A. Huml, Quintiles Inc., 4820 Emperor Blvd, Durham, NC 27703, USA   For newly diagnosed muscular dystrophy (MD) patients and their caregivers in the U.S., the first point…

read more

Pharmaceutical Products and Non-pharmaceutical Interventions as Potential Treatments for Patients with Muscular Dystrophy

May 10, 2017 by in NEUROLOGY Comments Off on Pharmaceutical Products and Non-pharmaceutical Interventions as Potential Treatments for Patients with Muscular Dystrophy

Fig. 12.1 FDA foundation building for clinical trial drug development As the scientific (e.g., pathophysiology, mechanism of action [MOA], effect of intervention) and clinical data (post IND phase, such as…

read more

Global Regulatory Landscape

May 10, 2017 by in NEUROLOGY Comments Off on Global Regulatory Landscape

Document Reference number Publication date Concept paper on the need for a guideline on the treatment of Duchenne and Becker muscular dystrophy EMA/CHMP/CNSWP/236981/2011 – Adoption by CHMP for release for…

read more

Orthopaedic Management of the Child with Muscular Dystrophy

May 10, 2017 by in NEUROLOGY Comments Off on Orthopaedic Management of the Child with Muscular Dystrophy

© Springer International Publishing Switzerland 2015Raymond A. Huml (ed.)Muscular Dystrophy10.1007/978-3-319-17362-7_9 9. Orthopaedic Management of the Child with Muscular Dystrophy Robert K. Lark1 and Elizabeth W. Hubbard1   (1) Department of Orthopaedic Surgery, Duke University Medical Center, Lenox Baker Children’s…

read more

Physical Therapy and Orthotic Devices

May 10, 2017 by in NEUROLOGY Comments Off on Physical Therapy and Orthotic Devices

DMD/BMD [2, 3, 6, 19, 30, 31, 33, 44] DMD/BMD weakness, as detailed in Chapter 4, tends to be symmetrical Characteristic weakness (early stage) Characteristic compensations/posture/patterns of movement (early stage)…

read more
Get Clinical Tree app for offline access